Back to search results

A Study to Investigate the Efficacy and Safety of an Infusion of IOV-4001 in Adult Participants With Unresectable or Metastatic Melanoma or Stage III or IV Non-small-cell Lung Cancer

Abroad (travel likely)RecruitingPHASE1, PHASE2

Conditions

Unresectable Melanoma · Metastatic Melanoma · Stage III Non-small Cell Lung Cancer · Stage IV Non-small Cell Lung Cancer

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

  • The Angeles Clinic and Research Institute, Los Angeles, California, United States

  • Sylvester Comprehensive Cancer Center, Miami, Florida, United States

  • Orlando Health Cancer Institute, Orlando, Florida, United States

  • Moffitt Cancer Center, Tampa, Florida, United States

  • The University of Kansas Cancer Center, Westwood, Kansas, United States

  • University of Louisville, Louisville, Kentucky, United States

  • Weill Medical College of Cornell University, New York, New York, United States

  • Memorial Sloan Kettering Cancer Center, New York, New York, United States

  • University of Cincinnati, Cincinnati, Ohio, United States

  • UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania, United States

  • Medical College of Wisconsin, Milwaukee, Wisconsin, United States

Study leads

  • Iovance Biotherapeutics Study Team

    Study Director

    Iovance Biotherapeutics

View source on ClinicalTrials.gov(opens in a new tab)